Global Research PartnershipsCreate free account
Industry Collaboration Index

Sector Award · Health and life sciences · 2026

Biotechnology and Advanced Therapies: the winner and finalists

10 finalist partnerships, chosen from 413 eligible university and company partnerships in the open record. The winner is listed first; the other finalists follow in alphabetical order of university. The winner in each category is the finalist with the highest partnership score (volume of joint work 40%, years active 30%, field-weighted citation impact 30%) in the frozen Edition 1 record. No panel, nomination or payment plays any part. Winners were announced with the index at 05:30 BST, Thursday 15 October 2026, after the corrections and opt-out window closed at 17:00 BST on Tuesday 13 October.

All award categoriesThe Biotechnology and Advanced Therapies sector index
★

Winner · partnership score 95.1, the highest in the category

University of Pennsylvania×Acuitas Therapeutics

United States · company based in Canada · 26 joint works in the sector · active 5 of 5 years · field-weighted citation impact 6.12
DW
Drew WeissmanAcademic co-author · University of Pennsylvania · 18 joint works in the partnership · ORCID
YT
Ying K. TamIndustry co-author · Acuitas Therapeutics · 20 joint works in the partnership · ORCID
“CAR T Cells Produced in vivo to Treat Cardiac Injury” (2023, 940 citations)
◆

ETH Zurich×Roche

Switzerland · company based in Switzerland · 16 joint works in the sector · active 5 of 5 years · field-weighted citation impact 4.71
BT
Barbara TreutleinAcademic co-author · ETH Zurich · 12 joint works in the partnership · ORCID
JC
J. Gray CampIndustry co-author · Roche · 3 joint works in the partnership · ORCID
“Single-cell epigenomic reconstruction of developmental trajectories from pluripotency in human neural organoid systems” (2024, 44 citations)
◆

Harvard University×Bristol-Myers Squibb

United States · company based in United States · 28 joint works in the sector · active 5 of 5 years · field-weighted citation impact 2.48
JA
Jeremy S. AbramsonAcademic co-author · Harvard University · 12 joint works in the partnership · ORCID
AC
Alessandro CrottaIndustry co-author · Bristol-Myers Squibb · 6 joint works in the partnership
“Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study” (2022, 395 citations)
◆

Huazhong University of Science and Technology×Nanjing IASO Biotechnology Co.

China · company based in China · 21 joint works in the sector · active 5 of 5 years · field-weighted citation impact 3.51
CL
Chunrui LiAcademic co-author · Huazhong University of Science and Technology · 11 joint works in the partnership · ORCID
GH
Guang HuIndustry co-author · Nanjing IASO Biotechnology Co. · 10 joint works in the partnership · ORCID
“A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma” (2021, 216 citations)
◆

Johannes Gutenberg University Mainz×BioNTech

Germany · company based in Germany · 22 joint works in the sector · active 5 of 5 years · field-weighted citation impact 2.54
ED
Eva Wagner-DrouetAcademic co-author · Johannes Gutenberg University Mainz · 2 joint works in the partnership · ORCID
BR
Benjamin RengstlIndustry co-author · BioNTech · 4 joint works in the partnership · ORCID
“CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial” (2023, 290 citations)
◆

Karolinska Institutet×AstraZeneca

Sweden · company based in United Kingdom · 26 joint works in the sector · active 5 of 5 years · field-weighted citation impact 2.31
SA
Samir EL AndaloussiAcademic co-author · Karolinska Institutet · 5 joint works in the partnership · ORCID
JW
John WisemanIndustry co-author · AstraZeneca · 4 joint works in the partnership · ORCID
“Extracellular vesicles transport RNA between cells: Unraveling their dual role in diagnostics and therapeutics” (2024, 60 citations)
◆

University of Basel×Roche

Switzerland · company based in Switzerland · 28 joint works in the sector · active 5 of 5 years · field-weighted citation impact 3.91
PR
Philippe RinglerAcademic co-author · University of Basel · 5 joint works in the partnership · ORCID
ML
Matthias E. LauerIndustry co-author · Roche · 6 joint works in the partnership · ORCID
“Investigations into mRNA Lipid Nanoparticles Shelf-Life Stability under Nonfrozen Conditions” (2023, 64 citations)
◆

University of California, Los Angeles×Gilead Sciences

United States · company based in United States · 14 joint works in the sector · active 5 of 5 years · field-weighted citation impact 3.54
GS
Gary John SchillerAcademic co-author · University of California, Los Angeles · 4 joint works in the partnership · ORCID
JD
Jinghui DongIndustry co-author · Gilead Sciences · 3 joint works in the partnership · ORCID
“Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study” (2022, 81 citations)
◆

University of Gothenburg×AstraZeneca

Sweden · company based in United Kingdom · 16 joint works in the sector · active 5 of 5 years · field-weighted citation impact 2.28
HV
Hadi ValadiAcademic co-author · University of Gothenburg · 4 joint works in the partnership · ORCID
SH
Sepideh Heydarkhan‐HagvallIndustry co-author · AstraZeneca · 3 joint works in the partnership
“Lipid Nanoparticles Deliver the Therapeutic VEGFA mRNA In Vitro and In Vivo and Transform Extracellular Vesicles for Their Functional Extensions” (2023, 91 citations)
◆

Washington University in St. Louis×Gilead Sciences

United States · company based in United States · 14 joint works in the sector · active 5 of 5 years · field-weighted citation impact 3.71
AG
Armin GhobadiAcademic co-author · Washington University in St. Louis · 11 joint works in the partnership · ORCID
HM
Harry H. MiaoIndustry co-author · Gilead Sciences · 4 joint works in the partnership · ORCID
“5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)” (2023, 242 citations)

Partnership score: volume of joint work 40%, years active 30%, field-weighted citation impact 30% (shrunk toward 1.0 when evidence is thin). Joint works count half where the only company author also holds a post at the university. The named researchers co-wrote the cited paper and represent a wider team. Full rules.